within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M09A_OtherDrugsForDisordersOfTheMusculoSkeletalSystem.M09AX05_AceneuramicAcid;

model AceneuramicAcid
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.1,
    Cl = 1.6666666666666667e-06,
    adminDuration = 600,
    adminMass = 6000 / 1000000,
    adminCount = 1,
    Vd = 0.042,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>AceneuramicAcid</td></tr><tr><td>ATC code:</td><td>M09AX05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>6000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>42</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Aceneuramic acid, also known as sialic acid or N-acetylneuraminic acid, is a monosaccharide widely found in animal tissues and is a key component of glycoproteins and gangliosides. It is used in rare metabolic disorders related to sialic acid metabolism and has been investigated for use in GNE myopathy (hereditary inclusion body myopathy). The drug is not widely approved for general clinical use but is under investigation and used in some compassionate programs.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies available; parameters estimated for oral administration in adult patients with GNE myopathy.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M09AX05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end AceneuramicAcid;
